產品屬性：
產品名稱 | LQZ-7I |
規格 | 10mM*1 mL in DMSO、5mg、10mg、25mg、50mg |
貨號 | EY-01Y12407 |
Cas No.: 195822-23-2
別名: N/A
化學名: N/A
分子式: C20H14F2N4
分子量: 348.35
溶解度: DMSO: 125 mg/mL (358.83 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
LQZ-7I is a surviving-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors[1].LQZ-7I has improved cytotoxicity with IC50s of 3.1 μM against C4-2 cells and 4.8 μM against PC-3 cells compared with the parent compound LQZ-7[1]. LQZ-7I (10 μM; 0-6 hours) treatment reduces the expression of survivin. However, LQZ-7I does not reduce the expression of XIAP, CIAP1, and CIAP2. LQZ-7I may be selective to its intended target survivin[1].Western Blot Analysis[1] Cell Line:PC-3 or C4-2 cellsLQZ-7I (100 mg/kg; oral gavage every other day for a total of ten treatments) significantly suppresses tumor growth without any notable adverse effect on the mice[1].Animal Model:6-week old male NSG mice[1][1]. Robert Peery,et al. Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation. J Med Chem. 2020 Jun 9.
特別提醒公司產品僅供科研使用
